160 related articles for article (PubMed ID: 16952136)
21. Structure-based in silico design of a high-affinity dipeptide inhibitor for novel protein drug target Shikimate kinase of Mycobacterium tuberculosis.
Kumar M; Verma S; Sharma S; Srinivasan A; Singh TP; Kaur P
Chem Biol Drug Des; 2010 Sep; 76(3):277-84. PubMed ID: 20626408
[TBL] [Abstract][Full Text] [Related]
22. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of types I and II dehydroquinase.
Le Sann C; Gower MA; Abell AD
Mini Rev Med Chem; 2004 Sep; 4(7):747-56. PubMed ID: 15379642
[TBL] [Abstract][Full Text] [Related]
24. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536
[No Abstract] [Full Text] [Related]
25. Mechanistic basis of the inhibition of type II dehydroquinase by (2S)- and (2R)-2-benzyl-3-dehydroquinic acids.
Lence E; Tizón L; Otero JM; Peón A; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; González-Bello C
ACS Chem Biol; 2013 Mar; 8(3):568-77. PubMed ID: 23198883
[TBL] [Abstract][Full Text] [Related]
26. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
[TBL] [Abstract][Full Text] [Related]
27. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
Peón A; Coderch C; Gago F; González-Bello C
ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
[TBL] [Abstract][Full Text] [Related]
28. Structure-aided design of inhibitors of Mycobacterium tuberculosis thymidylate kinase.
Van Calenbergh S
Verh K Acad Geneeskd Belg; 2006; 68(4):223-48. PubMed ID: 17214439
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.
Banerjee DR; Biswas R; Das AK; Basak A
Eur J Med Chem; 2015 Jul; 100():223-34. PubMed ID: 26092447
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the in vitro and intracellular efficacy of new monosubstituted sulfonylureas against extensively drug-resistant tuberculosis.
Wang D; Pan L; Cao G; Lei H; Meng X; He J; Dong M; Li Z; Liu Z
Int J Antimicrob Agents; 2012 Nov; 40(5):463-6. PubMed ID: 22867883
[TBL] [Abstract][Full Text] [Related]
31. Prioritization of natural compounds against mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study.
Lone MY; Athar M; Gupta VK; Jha PC
Biochem Biophys Res Commun; 2017 Sep; 491(4):1105-1111. PubMed ID: 28789944
[TBL] [Abstract][Full Text] [Related]
32. Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints.
Kumar A; Chaturvedi V; Bhatnagar S; Sinha S; Siddiqi MI
J Chem Inf Model; 2009 Jan; 49(1):35-42. PubMed ID: 19063713
[TBL] [Abstract][Full Text] [Related]
33. Molecular modeling of Mycobacterium tuberculosis dUTpase: docking and catalytic mechanism studies.
Ramalho TC; Caetano MS; Josa D; Luz GP; Freitas EA; da Cunha EF
J Biomol Struct Dyn; 2011 Jun; 28(6):907-17. PubMed ID: 21469751
[TBL] [Abstract][Full Text] [Related]
34. A 96-well microtiter plate assay for high-throughput screening of Mycobacterium tuberculosis dTDP-d-glucose 4,6-dehydratase inhibitors.
Shi X; Sha S; Liu L; Li X; Ma Y
Anal Biochem; 2016 Apr; 498():53-8. PubMed ID: 26778528
[TBL] [Abstract][Full Text] [Related]
35. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
[TBL] [Abstract][Full Text] [Related]
36. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
37. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
38. A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
Yang Y; Gao P; Liu Y; Ji X; Gan M; Guan Y; Hao X; Li Z; Xiao C
Bioorg Med Chem Lett; 2011 Jul; 21(13):3943-6. PubMed ID: 21641210
[TBL] [Abstract][Full Text] [Related]
39. New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening.
Kumar A; Siddiqi MI; Miertus S
J Mol Model; 2010 Apr; 16(4):693-712. PubMed ID: 19816720
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
